{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:13:57Z","timestamp":1762521237617},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2008,8,21]],"date-time":"2008-08-21T00:00:00Z","timestamp":1219276800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1007\/s00280-008-0814-7","type":"journal-article","created":{"date-parts":[[2008,8,20]],"date-time":"2008-08-20T05:57:55Z","timestamp":1219211875000},"page":"971-972","source":"Crossref","is-referenced-by-count":15,"title":["Acute hepatic failure following monotherapy with sunitinib for ovarian cancer"],"prefix":"10.1007","volume":"63","author":[{"given":"A.","family":"Taran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Ignatov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. D.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Bischoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,8,21]]},"reference":[{"issue":"7","key":"814_CR1","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2006.06.3602","volume":"25","author":"LQ Chow","year":"2007","unstructured":"Chow LQ, Eckhardt SG (2007) Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25(7):884\u2013896","journal-title":"J Clin Oncol"},{"issue":"5","key":"814_CR2","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1158\/1078-0432.CCR-06-2328","volume":"13","author":"VL Goodman","year":"2007","unstructured":"Goodman VL, Rock EP, Dagher R et al (2007) Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 13(5):1367\u20131373","journal-title":"Clin Cancer Res"},{"issue":"3","key":"814_CR3","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1124\/jpet.105.084145","volume":"315","author":"A Arora","year":"2005","unstructured":"Arora A, Scholar EM (2005) Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 315(3):971\u2013979","journal-title":"J Pharmacol Exp Ther"},{"issue":"21","key":"814_CR4","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1001\/jama.295.21.2516","volume":"295","author":"RJ Motzer","year":"2006","unstructured":"Motzer RJ, Rini BI, Bukowski RM et al (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295(21):2516\u20132524","journal-title":"JAMA"},{"issue":"3","key":"814_CR5","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00280-006-0376-5","volume":"60","author":"H Izzedine","year":"2007","unstructured":"Izzedine H, Buhaescu I, Rixe O et al (2007) Sunitinib malate. Cancer Chemother Pharmacol 60(3):357\u2013364","journal-title":"Cancer Chemother Pharmacol"},{"key":"814_CR6","doi-asserted-by":"crossref","first-page":"18s","DOI":"10.1200\/jco.2007.25.18_suppl.3546","volume":"25","author":"SJ Faivre","year":"2007","unstructured":"Faivre SJ, Raymond E, Douillard J et al (2007) Assessment of safety and drug-induced tumor necrosis with sunitinib in patients with unresectable hepatocellular carcinoma (HCC). J Clin Oncol 25:18s (supplement; abstract 3546)","journal-title":"J Clin Oncol"},{"key":"814_CR7","first-page":"18s","volume":"25","author":"AX Zhu","year":"2007","unstructured":"Zhu AX, Sahani DV, di Tomaso E (2007) A phase II study of sunitinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 25:18s (supplement; abstract 4637)","journal-title":"J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-008-0814-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-008-0814-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-008-0814-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T20:24:43Z","timestamp":1588883083000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-008-0814-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,21]]},"references-count":7,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["814"],"URL":"https:\/\/doi.org\/10.1007\/s00280-008-0814-7","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,21]]}}}